This is an excellent piece discussing AI's impact on biorisk, offering a great distillation of key topics. Definitely worth a read! (And I'm not surprised it's great, given that @csetgeorgetown.bsky.social's own @stephbatalis.bsky.social is quoted!) www.transformernews.ai/p/ai-biorisk...

Excited to share a new op-ed by @minanrn.bsky.social, @jessicaji.bsky.social, and myself for the National Interest! The administration's new AI Executive Order, aiming to suppress state-level AI regulation, risks undermining the innovation it seeks to advance. nationalinterest.org/blog/techlan...

With all sorts of new biotechnologies expanding what's possible in the life sciences, what's the best approach for the next era of biosecurity? Check out this new op-ed by @stephbatalis.bsky.social and myself for the 80th anniversary of @thebulletin.org! thebulletin.org/premium/2025...

Check out my new @csetgeorgetown.bsky.social report, written alongside @minanrn.bsky.social, @jessicaji.bsky.social, and Ngor Luong! cset.georgetown.edu/publication/... Identifying assumptions can help policymakers make informed, flexible decisions about AI under uncertainty.

More on the recent AI Action Plan! @csetgeorgetown.bsky.social work is very relevant.

Yesterday's new AI Action Plan has a lot worth discussing! One interesting aspect is its statement that the federal government should withhold AI-related funding from states with "burdensome AI regulations." This could be cause for concern.

Really timely breakdown of today's big AI Action Plan release, by @csetgeorgetown.bsky.social's own @alexfriedland.bsky.social! Give it a read, I think it's really useful.

Banning state-level AI regulation is a bad idea! One crucial reason is that states play a critical role in building AI governance infrastructure. Check out this new op-ed by @jessicaji.bsky.social, myself, and @minanrn.bsky.social on this topic! thehill.com/opinion/tech...

Antimicrobial resistance is a huge issue and an oft-forgotten killer. It kills more people each year than HIV/AIDS or malaria. This article is fascinating- it points out that while much of the AMR prevention discussion focuses on overuse of antimicrobials, underuse can also be a major issue.

"Red-teaming" isn't a catch-all term (or methodology!) to evaluate AI safety. So, what else do we have in the toolbox? In our recent blog post, we explore the different questions we can ask about safety, how we can start to measure them, and what it means for AIxBio. Check it out! ⬇️

Amidst all the discussion about AI safety, how exactly do we figure out whether a model is safe? There's no perfect method, but safety evaluations are the best tool we have. That said, different evals answer different questions about a model!

News like this isn't just a concern for public health practitioners - it should also be a big red flag for U.S. national security folks. America's biodefense strategy uses robust health infrastructure to deter bad actors. Right now, we're tearing down our own defenses so adversaries don't have to.

🚨 Latest op-ed is out in Defense One! “Dismantling critical preparedness offices, cutting infrastructure and funding, and allowing misinformation to derail the response are not just bad for healthcare—they’re dangerous national security signals.” www.defenseone.com/ideas/2025/0...

Have you heard of the Bayh-Dole Act? It's niche, but an incredibly important factor in the U.S. innovation ecosystem! For the National Interest, @jack-corrigan.bsky.social and I discuss a potential change that could benefit public access to medical drugs. nationalinterest.org/blog/techlan...

For @thebulletin.org, @stephbatalis.bsky.social and I break down the choices that DNA synthesis companies have to make when they screen customers- deciding how much expertise is enough. If you were in their shoes, where would you draw the line? Check it out here! thebulletin.org/2025/04/how-...

Companies that sell synthesized DNA need to screen their customers, lest sequences for pathogens or toxins fall into the wrong hands. How? Here are three recommendations. "How to stop bioterrorists from buying dangerous DNA," by @stephbatalis.bsky.social and @vikramvenkatram.bsky.social. ⬇️

Some CSET highlights from this year!

@csetgeorgetown.bsky.social just put out our AI Action Plan Response. It's a great summary of some of CSET's key recommendations on various aspects of AI policy! cset.georgetown.edu/publication/... Re: AI x bio policy, the piece mentions a few of our key findings. I'd like to discuss them here:

A really great and insightful data-driven piece from my colleague @stephbatalis.bsky.social, underscoring the importance of NIH and NSF funding for biotech. Worth a read!

With a changing landscape for AI and emerging tech policy, there's no better time to start following my @csetgeorgetown.bsky.social colleagues. We publish evidence-based, data-driven, and analytically rigorous work on a wide range of tech policy topics! Follow us here: bsky.app/starter-pack...

This is a fantastic new report from @stephbatalis.bsky.social! It breaks down how AI specifically impacts biorisk, and discusses the particular policy tools usable at each stage to reduce risk. Definitely worth a read!

Worried about biological threats in the age of AI? A new report from @stephbatalis.bsky.social breaks down the steps into planning and design to execution phases. Understanding these pathways can help us implement safeguards and promote innovation. More: cset.georgetown.edu/publication/...

Chemical and biological AI models vary in type, with different users, use cases, outputs, and capabilities. Each needs targeted safety evaluations. Check out my and @stephbatalis.bsky.social's new response to a NIST/AISI RFI on chem-bio models! cset.georgetown.edu/publication/...